Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MTEX | PRESS-RELEASE | bullish | 6/10 | Mannatech reported Q2 2026 net sales of $26.7M, up $1.0M YoY, and swung to net income of $1.0M ($0.53/diluted share) fro | Aug 12, 2026 |
| KURA | PRESS-RELEASE | bullish | 6/10 | Kura Oncology reported Q1 2026 earnings with an EPS of -$0.83, beating consensus of -$0.88 by 5.7%, and revenue of $20.2 | Aug 12, 2026 |
| HYPD | PRESS-RELEASE | bullish | 7/10 | Hyperion DeFi reported Q2 2026 GAAP net income of $31.0M, a second consecutive record, driven by $54.8M in non-GAAP trea | Aug 12, 2026 |
| SPRO | PRESS-RELEASE | neutral | 4/10 | Spero Therapeutics reported Q2 2026 financial results, highlighting a net loss of $11.0 million for the quarter, compare | Aug 12, 2026 |
| AVBP | PRESS-RELEASE | bearish | 6/10 | ArriVent reported Q2 2026 EPS of -$1.05, a 16.7% miss vs consensus of -$0.98, with net loss widening to $49.9M from $31. | Aug 12, 2026 |
| DERM | PRESS-RELEASE | bearish | 6/10 | Journey Medical reported Q1 2026 EPS of -$0.08, a 255.6% miss vs consensus of -$0.02, with revenue of $18.5M slightly ab | Aug 12, 2026 |
| MNPR | PRESS-RELEASE | bullish | 6/10 | Monopar Therapeutics reported a Q2 2026 net loss of $5.3M ($0.62/share), wider than the $2.5M loss in Q2 2025, driven by | Aug 12, 2026 |
| APRE | PRESS-RELEASE | neutral | 5/10 | Aprea Therapeutics reported Q2 2026 results with a net loss of $3.6M ($-0.07/share), widening from a $3.2M loss in Q2 20 | Aug 12, 2026 |
| DYAI | PRESS-RELEASE | bearish | 7/10 | Dyadic International reported Q2 2026 revenue of $961,138, essentially flat year-over-year (-0.6%), and a net loss of $2 | Aug 12, 2026 |
| IPSC | PRESS-RELEASE | bearish | 5/10 | Century Therapeutics reported Q2 2026 EPS of -$0.17, a 55.3% miss vs consensus of -$0.11, with no revenue. The company h | Aug 12, 2026 |
| ALT | PRESS-RELEASE | neutral | 5/10 | Altimmune reported Q2 2026 net loss of $0.12 per share, beating consensus of -$0.13 by 7.7%, but this is a mechanical ar | Aug 12, 2026 |
| ADAG | PRESS-RELEASE | mixed | 6/10 | Adagene reported H1 2026 net loss of $16.4M, wider than $13.5M in H1 2025, with EPS of -$0.23 vs consensus -$0.08 (a 187 | Aug 12, 2026 |
| ABUS | PRESS-RELEASE | bullish | 7/10 | Arbutus Biopharma reported Q2 2026 revenue of $1.0M (down from $10.7M YoY due to the prior year's Qilu partnership reven | Aug 12, 2026 |
| XLO | PRESS-RELEASE | bullish | 7/10 | Xilio Therapeutics reported Q2 2026 collaboration revenue of $18.7M (up 131% YoY) and a net loss of $6.4M (improved from | Aug 12, 2026 |
| LQDA | PRESS-RELEASE | bearish | 6/10 | Liquidia reported Q2 2026 net product sales of $170.4M (+31% QoQ), net income of $74.7M ($0.74 diluted EPS), and adjuste | Aug 12, 2026 |
| PHVS | PRESS-RELEASE | bullish | 7/10 | Pharvaris reported Q2 2026 EPS of -€0.70, a beat vs consensus of -$0.65 (9.7% beat), with no revenue. The company has €3 | Aug 12, 2026 |
| ANNX | PRESS-RELEASE | bullish | 6/10 | Annexon reported Q2 2026 EPS of -$0.28, slightly wider than the prior year's -$0.34 loss, but the focus is on pipeline c | Aug 12, 2026 |
| STRO | PRESS-RELEASE | mixed | 6/10 | Sutro Biopharma reported Q2 2026 revenue of $9.8M (down 84.6% YoY from $63.7M) and a net loss of $38.5M (-$2.33 EPS), si | Aug 12, 2026 |
| HUMA | PRESS-RELEASE | bullish | 7/10 | Humacyte reported Q2 2026 EPS of -$0.09, beating consensus of -$0.10 by 12.9%, with Symvess product revenue of $0.4M (up | Aug 12, 2026 |
| LXEO | PRESS-RELEASE | neutral | 5/10 | Lexeo Therapeutics reported Q2 2026 EPS of -$0.30, beating consensus of -$0.28 by 10.3% (a beat), with net loss narrowin | Aug 12, 2026 |
| TCRX | PRESS-RELEASE | bearish | 6/10 | TScan Therapeutics reported Q2 2026 EPS of -$0.23, a 15% miss vs consensus of -$0.20, and revenue of $1.1M, sharply down | Aug 12, 2026 |
| ABOS | PRESS-RELEASE | bearish | 5/10 | Acumen Pharmaceuticals reported Q2 2026 EPS of -$0.45 (GAAP), missing the Street consensus of -$0.39, while net loss nar | Aug 12, 2026 |
| TECH | PRESS-RELEASE | neutral | 4/10 | Bio-Techne reported Q4 FY2026 adjusted EPS of $0.52, a 2.1% beat vs $0.52 consensus, on revenue of $321.2M (1% reported | Aug 12, 2026 |
| SLXN | PRESS-RELEASE | bearish | 7/10 | Silexion Therapeutics priced a public offering of 3,846,161 ordinary shares (or equivalents) and series E warrants at $0 | Aug 11, 2026 |
| EPRX | PRESS-RELEASE | neutral | 4/10 | Eupraxia Pharmaceuticals reported Q2 2026 financial results with a net loss of $14.5M, up from $8.7M a year ago, driven | Aug 11, 2026 |
| BBOT | PRESS-RELEASE | neutral | 2/10 | BridgeBio Oncology Therapeutics (BBOT) awarded inducement stock grants to two new employees under its 2025 Inducement Pl | Aug 11, 2026 |
| CRDF | PRESS-RELEASE | bearish | 6/10 | Cardiff Oncology reported Q2 2026 EPS of -$0.18, missing consensus of -$0.16 by 12.5%, with revenue of $104K (below $63K | Aug 11, 2026 |
| LENZ | PRESS-RELEASE | mixed | 5/10 | LENZ Therapeutics reported Q2 2026 revenue of $5.5M (beating $2.4M consensus) and EPS of -$1.02 (beating -$1.07 consensu | Aug 11, 2026 |
| AARD | PRESS-RELEASE | bearish | 7/10 | Aardvark Therapeutics reported Q2 2026 EPS of -$0.66, a 12.3% miss vs consensus of -$0.88, with zero revenue. The compan | Aug 11, 2026 |
| KYTX | PRESS-RELEASE | neutral | 5/10 | Kyverna Therapeutics reported Q2 2026 net loss of $0.63 per share, beating consensus of -$0.68 by 7.4%. The company high | Aug 11, 2026 |